Table 2.
Relationship between ZFP57 expression and clinical pathological parameters of patients in serous ovarian cancer.
| ZFP57 High | ZFP57 Low | Total | χ2 | P | ||
|---|---|---|---|---|---|---|
| Serous OC | 66 (53.7%) | 57 (46.3%) | 123 | 23.607 | <0.001 | |
| ovarian cyst | 7 (13.7%) | 44 (86.3%) | 51 | |||
| Age | ||||||
| ≤50 | 19 (50.0%) | 19 (50.0%) | 38 | 0.296 | 0.586 | |
| >50 | 47 (55.3%) | 38 (44.7%) | 85 | |||
| Grade | ||||||
| high-grade serous | 56 (65.1%) | 30 (34.9%) | 86 | 13.062 | <0.001 | |
| low-grade serous | 11 (29.7%) | 26 (70.3%) | 37 | |||
| Stage | ||||||
| I | 11 (28.9%) | 27 (71.1%) | 38 | 21.147 | <0.001 | |
| II | 7 (36.8%) | 12 (63.2%) | 19 | |||
| III | 37 (72.5%) | 14 (27.5%) | 51 | |||
| IV | 11 (73.3%) | 4 (26.7%) | 15 | |||
| Total | 66 (53.7%) | 57 (46.3%) | 123 |